At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 752 enrolled
Drug / intervention
2 mg perampanel +2 moredrug
Likely dose
2 mg perampanelfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations
In Brief
A Phase 3 clinical trial evaluating 2 mg perampanel, 4 mg perampanel, and 1 other intervention for Parkinson's Disease. Completed, enrolled 752 participants across 114 sites in 2 countries.
Detailed Summary
This is a multi-center, randomized, double-blind, placebo-controlled, parallel-group study of E2007 in levodopa treated Parkinson's disease patients with motor fluctuations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedAug 2006
Primary CompletionJan 2008
TodayJul 2026
First PostedAug 24, 2006
Enrollment StartAug 1, 2006
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 19.9 years ago
Interventions
2 mg perampaneldrug
2 mg perampanel
4 mg perampaneldrug
4 mg perampanel
placebo comparatordrug
placebo comparator